MiMedx Group Résultats passés
Passé contrôle des critères 2/6
MiMedx Group a connu une croissance annuelle moyenne de ses bénéfices de 61.9%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en hausse à 36.2% par an. Les revenus ont augmenté de en hausse à un taux moyen de 10.8% par an. Le rendement des capitaux propres de MiMedx Group est 12.6% et ses marges nettes sont de 7.9%.
Informations clés
61.86%
Taux de croissance des bénéfices
62.12%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.04% |
| Taux de croissance des recettes | 10.81% |
| Rendement des fonds propres | 12.64% |
| Marge nette | 7.88% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking Alpha
Mise à jour du récit • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
Nouveau récit • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.
Nouveau récit • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.Mise à jour du récit • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.Mise à jour du récit • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.Mise à jour du récit • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.Mise à jour du récit • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.Mise à jour du récit • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.Article d’analyse • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Article d’analyse • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...Article d’analyse • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Article d’analyse • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Article d’analyse • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...Article d’analyse • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d’analyse • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Article d’analyse • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...
Nouveau récit • Sep 24
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.Article d’analyse • May 21
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
MiMedx Group, Inc. ( NASDAQ:MDXG ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Article d’analyse • May 14
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment MiMedx Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 389 | 31 | 259 | 16 |
| 31 Dec 25 | 419 | 49 | 266 | 15 |
| 30 Sep 25 | 393 | 41 | 254 | 14 |
| 30 Jun 25 | 364 | 32 | 239 | 13 |
| 31 Mar 25 | 352 | 40 | 221 | 13 |
| 31 Dec 24 | 349 | 42 | 216 | 12 |
| 30 Sep 24 | 343 | 79 | 210 | 11 |
| 30 Jun 24 | 340 | 79 | 209 | 11 |
| 31 Mar 24 | 335 | 68 | 216 | 12 |
| 31 Dec 23 | 321 | 56 | 216 | 13 |
| 30 Sep 23 | 309 | 19 | 215 | 6 |
| 30 Jun 23 | 295 | 2 | 219 | 8 |
| 31 Mar 23 | 281 | -18 | 225 | 10 |
| 31 Dec 22 | 268 | -27 | 221 | 13 |
| 30 Sep 22 | 261 | -34 | 216 | 22 |
| 30 Jun 22 | 256 | -28 | 209 | 20 |
| 31 Mar 22 | 258 | -19 | 202 | 19 |
| 31 Dec 21 | 242 | -18 | 199 | 10 |
| 30 Sep 21 | 260 | -35 | 223 | 16 |
| 30 Jun 21 | 261 | -83 | 233 | 15 |
| 31 Mar 21 | 246 | -88 | 231 | 13 |
| 31 Dec 20 | 248 | -83 | 240 | 12 |
| 30 Sep 20 | 256 | -73 | 212 | 11 |
| 30 Jun 20 | 281 | -8 | 210 | 10 |
| 31 Mar 20 | 294 | -17 | 233 | 11 |
| 31 Dec 19 | 299 | -26 | 265 | 11 |
| 30 Sep 19 | 315 | -54 | 270 | 13 |
| 30 Jun 19 | 314 | -67 | 287 | 14 |
| 31 Mar 19 | 342 | -48 | 295 | 15 |
| 31 Dec 18 | 359 | -30 | 295 | 16 |
| 30 Sep 18 | 354 | 41 | 275 | 15 |
| 30 Jun 18 | 352 | 59 | 260 | 16 |
| 31 Mar 18 | 333 | 65 | 235 | 17 |
| 31 Dec 17 | 321 | 65 | 220 | 18 |
| 30 Sep 17 | 303 | 35 | 216 | 18 |
| 30 Jun 17 | 283 | 21 | 205 | 15 |
| 31 Mar 17 | 264 | 15 | 192 | 14 |
| 31 Dec 16 | 222 | 0 | 172 | 14 |
| 30 Sep 16 | 227 | 20 | 168 | 11 |
| 30 Jun 16 | 212 | 23 | 154 | 10 |
| 31 Mar 16 | 200 | 27 | 144 | 9 |
| 31 Dec 15 | 187 | 29 | 133 | 8 |
| 30 Sep 15 | 175 | 20 | 126 | 8 |
| 30 Jun 15 | 160 | 17 | 115 | 8 |
Des revenus de qualité: MDXG a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de MDXG sont inférieures à celles de l'année dernière MDXG. (7.9%) sont inférieures à celles de l'année dernière (11.3%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: MDXG est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 61.9% par an.
Accélération de la croissance: MDXG a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: MDXG a enregistré une croissance négative de ses bénéfices ( -23.2% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Biotechs ( 54.5% ).
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de MDXG ( 12.6% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/02 07:21 |
| Cours de l'action en fin de journée | 2026/06/02 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
MiMedx Group, Inc. est couverte par 11 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |